China Medical GatewayLoading your healthcare gateway…

Pancreatic Cancer in China

Overview

Pancreatic cancer — usually ductal adenocarcinoma — is aggressive and frequently diagnosed late. Outcomes depend strongly on treatment at experienced high-volume centers where surgery, pathology and oncology are tightly integrated.

China’s major pancreatic centers perform very high volumes of Whipple procedures and have pioneered neoadjuvant strategies that convert borderline tumors to resectable ones.

Symptoms & Signs

Painless jaundice: yellowing of skin and eyes, dark urine and pale stools

Upper abdominal pain boring through to the back

Unexplained weight loss and new-onset diabetes in older adults

Loss of appetite, fatigue and nausea

New or worsening depression occasionally preceding diagnosis

Steatorrhea — greasy, floating stools — from enzyme insufficiency

Diagnosis

Pancreas-protocol contrast CT defining vessel involvement and resectability

MRI/MRCP mapping the bile and pancreatic ducts

Endoscopic ultrasound (EUS) with fine-needle biopsy for tissue confirmation

CA19-9 tumor marker for prognosis and monitoring

Genetic profiling including BRCA and MSI to guide therapy

Diagnostic laparoscopy excluding occult peritoneal spread

Treatment Options

Whipple pancreaticoduodenectomy — the definitive operation for head tumors — at high-volume centers

Distal pancreatectomy for body and tail tumors, increasingly laparoscopic or robotic

Neoadjuvant chemotherapy converting borderline tumors to resectable status

FOLFIRINOX or gemcitabine-based chemotherapy for advanced disease

Precision radiotherapy (SBRT) for locally advanced tumors and pain control

Early integration of pain management, nutrition and pancreatic-enzyme support

Advanced Technologies & Novel Drug

Robotic and laparoscopic Whipple procedures with low complication rates

ICG fluorescence navigation during pancreatic surgery

ERAS recovery protocols after major pancreatic resection

SBRT and adaptive radiotherapy targeting locally advanced tumors

Novel second-line chemotherapy and targeted agents accessible through major-center programs

Hospital & Specialist

Return to Home